Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cilostazol (Primary) ; Aspirin; Clopidogrel
Indications Myocardial infarction; Thrombosis
Focus Therapeutic Use
Acronyms SILOAM

Most Recent Events

15 Nov 2021 Primary endpoint has (Major Adverse Cardiovascular and Cerebral Events) not been met according to the results presented at the American Heart Association Scientific Sessions 2021
15 Nov 2021 Results presented at the American Heart Association Scientific Sessions 2021
18 Feb 2020 Planned End Date changed from 28 Sep 2019 to 1 Mar 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight